These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1282887

  • 21. Human insulin-like growth factor I receptor 950tyrosine is required for somatotroph growth factor signal transduction.
    Yamasaki H, Prager D, Gebremedhin S, Melmed S.
    J Biol Chem; 1992 Oct 15; 267(29):20953-8. PubMed ID: 1400411
    [Abstract] [Full Text] [Related]

  • 22. Processing of mutated proinsulin with tetrabasic cleavage sites to mature insulin reflects the expression of furin in nonendocrine cell lines.
    Yanagita M, Hoshino H, Nakayama K, Takeuchi T.
    Endocrinology; 1993 Aug 15; 133(2):639-44. PubMed ID: 8344203
    [Abstract] [Full Text] [Related]

  • 23. Contribution of residues A54 and L55 of the human insulin-like growth factor-II (IGF-II) A domain to Type 2 IGF receptor binding specificity.
    Forbe BE, McNeil KA, Scott CD, Surinya KH, Cosgrove LJ, Wallace JC.
    Growth Factors; 2001 Aug 15; 19(3):163-73. PubMed ID: 11811790
    [Abstract] [Full Text] [Related]

  • 24. Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions.
    Payet LD, Wang XH, Baxter RC, Firth SM.
    Endocrinology; 2003 Jul 15; 144(7):2797-806. PubMed ID: 12810533
    [Abstract] [Full Text] [Related]

  • 25. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II.
    Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC.
    Biochem J; 1993 Aug 01; 293 ( Pt 3)(Pt 3):713-9. PubMed ID: 7688957
    [Abstract] [Full Text] [Related]

  • 26. An insulin-like growth factor II (IGF-II) affinity-enhancing domain localized within extracytoplasmic repeat 13 of the IGF-II/mannose 6-phosphate receptor.
    Devi GR, Byrd JC, Slentz DH, MacDonald RG.
    Mol Endocrinol; 1998 Nov 01; 12(11):1661-72. PubMed ID: 9817593
    [Abstract] [Full Text] [Related]

  • 27. Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding.
    Garmroudi F, Devi G, Slentz DH, Schaffer BS, MacDonald RG.
    Mol Endocrinol; 1996 Jun 01; 10(6):642-51. PubMed ID: 8776724
    [Abstract] [Full Text] [Related]

  • 28. Altered affinity of insulin-like growth factor II (IGF-II) for receptors and IGF-binding proteins, resulting from limited modifications of the IGF-II molecule.
    Oh Y, Beukers MW, Pham HM, Smanik PA, Smith MC, Rosenfeld RG.
    Biochem J; 1991 Aug 15; 278 ( Pt 1)(Pt 1):249-54. PubMed ID: 1715685
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor.
    Jansson M, Uhlen M, Nilsson B.
    Biochemistry; 1997 Apr 08; 36(14):4108-17. PubMed ID: 9100004
    [Abstract] [Full Text] [Related]

  • 33. Two insulin-like growth factor (IGF)-binding proteins are responsible for the selective affinity for IGF-II of cerebrospinal fluid binding proteins.
    Roghani M, Lassarre C, Zapf J, Povoa G, Binoux M.
    J Clin Endocrinol Metab; 1991 Sep 08; 73(3):658-66. PubMed ID: 1714916
    [Abstract] [Full Text] [Related]

  • 34. Recombinant canine single chain insulin analogues: insulin receptor binding capacity and ability to stimulate glucose uptake.
    Adams JP, Holder AL, Catchpole B.
    Vet J; 2014 Dec 08; 202(3):436-42. PubMed ID: 25457265
    [Abstract] [Full Text] [Related]

  • 35. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.
    Arai T, Busby W, Clemmons DR.
    Endocrinology; 1996 Nov 08; 137(11):4571-5. PubMed ID: 8895319
    [Abstract] [Full Text] [Related]

  • 36. Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling.
    Devi GR, Yang DH, Rosenfeld RG, Oh Y.
    Endocrinology; 2000 Nov 08; 141(11):4171-9. PubMed ID: 11089550
    [Abstract] [Full Text] [Related]

  • 37. Phosphorylation of IGFBP-1 at discrete sites elicits variable effects on IGF-I receptor autophosphorylation.
    Abu Shehab M, Iosef C, Wildgruber R, Sardana G, Gupta MB.
    Endocrinology; 2013 Mar 08; 154(3):1130-43. PubMed ID: 23354097
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.